HAE Relative Valuation
HAE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HAE is overvalued; if below, it's undervalued.
Historical Valuation
Haemonetics Corp (HAE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.49 is considered Undervalued compared with the five-year average of 20.91. The fair price of Haemonetics Corp (HAE) is between 123.97 to 178.32 according to relative valuation methord. Compared to the current price of 83.00 USD , Haemonetics Corp is Undervalued By 33.05%.
Relative Value
Fair Zone
123.97-178.32
Current Price：83.00
33.05%
Undervalued
15.49
PE
1Y
3Y
5Y
10.55
EV/EBITDA
Haemonetics Corp. (HAE) has a current EV/EBITDA of 10.55. The 5-year average EV/EBITDA is 13.48. The thresholds are as follows: Strongly Undervalued below 5.73, Undervalued between 5.73 and 9.60, Fairly Valued between 17.35 and 9.60, Overvalued between 17.35 and 21.22, and Strongly Overvalued above 21.22. The current Forward EV/EBITDA of 10.55 falls within the Historic Trend Line -Fairly Valued range.
12.79
EV/EBIT
Haemonetics Corp. (HAE) has a current EV/EBIT of 12.79. The 5-year average EV/EBIT is 17.37. The thresholds are as follows: Strongly Undervalued below 8.55, Undervalued between 8.55 and 12.96, Fairly Valued between 21.78 and 12.96, Overvalued between 21.78 and 26.19, and Strongly Overvalued above 26.19. The current Forward EV/EBIT of 12.79 falls within the Undervalued range.
2.76
PS
Haemonetics Corp. (HAE) has a current PS of 2.76. The 5-year average PS is 3.17. The thresholds are as follows: Strongly Undervalued below 1.39, Undervalued between 1.39 and 2.28, Fairly Valued between 4.06 and 2.28, Overvalued between 4.06 and 4.95, and Strongly Overvalued above 4.95. The current Forward PS of 2.76 falls within the Historic Trend Line -Fairly Valued range.
13.54
P/OCF
Haemonetics Corp. (HAE) has a current P/OCF of 13.54. The 5-year average P/OCF is 12.48. The thresholds are as follows: Strongly Undervalued below -4.05, Undervalued between -4.05 and 4.21, Fairly Valued between 20.74 and 4.21, Overvalued between 20.74 and 29.00, and Strongly Overvalued above 29.00. The current Forward P/OCF of 13.54 falls within the Historic Trend Line -Fairly Valued range.
15.86
P/FCF
Haemonetics Corp. (HAE) has a current P/FCF of 15.86. The 5-year average P/FCF is 10.21. The thresholds are as follows: Strongly Undervalued below -10.38, Undervalued between -10.38 and -0.08, Fairly Valued between 20.51 and -0.08, Overvalued between 20.51 and 30.80, and Strongly Overvalued above 30.80. The current Forward P/FCF of 15.86 falls within the Historic Trend Line -Fairly Valued range.
Haemonetics Corp (HAE) has a current Price-to-Book (P/B) ratio of 4.40. Compared to its 3-year average P/B ratio of 4.45 , the current P/B ratio is approximately -1.08% higher. Relative to its 5-year average P/B ratio of 4.71, the current P/B ratio is about -6.59% higher. Haemonetics Corp (HAE) has a Forward Free Cash Flow (FCF) yield of approximately 6.84%. Compared to its 3-year average FCF yield of 3.73%, the current FCF yield is approximately 83.60% lower. Relative to its 5-year average FCF yield of 3.05% , the current FCF yield is about 124.34% lower.
4.40
P/B
Median3y
4.45
Median5y
4.71
6.84
FCF Yield
Median3y
3.73
Median5y
3.05
Competitors Valuation Multiple
The average P/S ratio for HAE's competitors is 5.88, providing a benchmark for relative valuation. Haemonetics Corp Corp (HAE) exhibits a P/S ratio of 2.76, which is -53.02% above the industry average. Given its robust revenue growth of -5.27%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HAE increased by 19.87% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 9.79 to 11.82.
The secondary factor is the P/E Change, contributed 4.40%to the performance.
Overall, the performance of HAE in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
SKT
Tanger Inc
33.92USD
-0.38%
FROG
Jfrog Ltd
62.96USD
6.39%
ASO
Academy Sports and Outdoors Inc
56.89USD
-2.77%
SHC
Sotera Health Co
18.8USD
0.37%
ALIT
Alight Inc
1.75USD
-7.89%
RUM
Rumble Inc
6.61USD
-1.64%
ATGE
Adtalem Global Education Inc
109.95USD
-0.52%
IAC
IAC Inc
38.58USD
-2.50%
GFF
Griffon Corp
74.46USD
-2.41%
KFY
Korn Ferry
66.59USD
0.00%
Frequently Asked Questions
Is Haemonetics Corp (HAE) currently overvalued or undervalued?
Haemonetics Corp (HAE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.49 is considered Undervalued compared with the five-year average of 20.91. The fair price of Haemonetics Corp (HAE) is between 123.97 to 178.32 according to relative valuation methord. Compared to the current price of 83.00 USD , Haemonetics Corp is Undervalued By 33.05% .
What is Haemonetics Corp (HAE) fair value?
HAE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Haemonetics Corp (HAE) is between 123.97 to 178.32 according to relative valuation methord.
How does HAE's valuation metrics compare to the industry average?
The average P/S ratio for HAE's competitors is 5.88, providing a benchmark for relative valuation. Haemonetics Corp Corp (HAE) exhibits a P/S ratio of 2.76, which is -53.02% above the industry average. Given its robust revenue growth of -5.27%, this premium appears unsustainable.
What is the current P/B ratio for Haemonetics Corp (HAE) as of Jan 07 2026?
As of Jan 07 2026, Haemonetics Corp (HAE) has a P/B ratio of 4.40. This indicates that the market values HAE at 4.40 times its book value.
What is the current FCF Yield for Haemonetics Corp (HAE) as of Jan 07 2026?
As of Jan 07 2026, Haemonetics Corp (HAE) has a FCF Yield of 6.84%. This means that for every dollar of Haemonetics Corp’s market capitalization, the company generates 6.84 cents in free cash flow.
What is the current Forward P/E ratio for Haemonetics Corp (HAE) as of Jan 07 2026?
As of Jan 07 2026, Haemonetics Corp (HAE) has a Forward P/E ratio of 15.49. This means the market is willing to pay $15.49 for every dollar of Haemonetics Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Haemonetics Corp (HAE) as of Jan 07 2026?
As of Jan 07 2026, Haemonetics Corp (HAE) has a Forward P/S ratio of 2.76. This means the market is valuing HAE at $2.76 for every dollar of expected revenue over the next 12 months.